Abstract
Background and Objective: This review, as part of the special series titled “Peritoneal Carcinomatosis: History and Future,” aims to describe the characteristics and disease burden of peritoneal metastasis from colorectal cancer (CRC), summarize its current treatments, and assess novel treatments that may aid in combatting this debilitating disease. The peritoneum is the 3rd most common site of metastasis from CRC. Patients with peritoneal metastases from CRC may be treated with a combination of cytoreductive surgery, hyperthermic intraperitoneal chemotherapy (HIPEC), and systemic chemotherapy, but even with current care practices, the 5-year overall survival is around 40%. Various novel therapies are being tested in the hopes of improving outcomes for these patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
